tirzepatide fda ruling Eli Lilly sues companies selling alternative versions of its weight loss drug Tirzepatide Lawsuit Against the FDA:

1 in the ongoing litigation

Do not rely on protein alone

Inflammasomes: mechanism of assembly, regulation and signalling

The complaints also allege that the touted studies are on individual ingredients and do not actually measure the extracts together in a single supplement, so that "while they claim to have clinical support for the components of Lemme GLP-1 Daily, they did not study the combination of those extracts in a single supplementmeaning that the supplement has not been clinically tested." Many courts, including those in New York and California, preclude private individuals from challenging advertising based on the advertiser lacking adequate substantiation for their claims, as the plaintiffs have done in the Lemme complaints